Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea

CompletedOBSERVATIONAL
Enrollment

682

Participants

Timeline

Start Date

September 23, 2013

Primary Completion Date

January 11, 2016

Study Completion Date

January 11, 2016

Conditions
Diphtheria-Tetanus-acellular Pertussis Vaccines
Interventions
BIOLOGICAL

Boostrix

Single intramuscular injection

OTHER

Safety data collection

Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form

Trial Locations (1)

443-380

GSK Investigational Site, Suwon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01929291 - Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea | Biotech Hunter | Biotech Hunter